US7214787B1
(en)
*
|
1993-09-21 |
2007-05-08 |
United States Of America As Represented By The Secretary Of The Army |
Recombinant vaccine against botulinum neurotoxin
|
US6967088B1
(en)
*
|
1995-03-16 |
2005-11-22 |
Allergan, Inc. |
Soluble recombinant botulinum toxin proteins
|
GB9508204D0
(en)
*
|
1995-04-21 |
1995-06-07 |
Speywood Lab Ltd |
A novel agent able to modify peripheral afferent function
|
GB9617671D0
(en)
|
1996-08-23 |
1996-10-02 |
Microbiological Res Authority |
Recombinant toxin fragments
|
US8012491B2
(en)
*
|
1996-08-23 |
2011-09-06 |
Syntaxin, Ltd. |
Recombinant toxin fragments
|
US7192596B2
(en)
*
|
1996-08-23 |
2007-03-20 |
The Health Protection Agency Ipsen Limited |
Recombinant toxin fragments
|
US7455845B2
(en)
*
|
1997-07-15 |
2008-11-25 |
The Regents Of The University Of Colorado |
Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure
|
PT2145629E
(pt)
*
|
1997-07-15 |
2012-04-16 |
Univ Colorado Regents |
Uso de terapia com neurotoxinas para o tratamento de perturbações urológicas e perturbações relacionadas
|
US9066943B2
(en)
*
|
1997-07-15 |
2015-06-30 |
The Regents Of The University Of Colorado |
Use of botulinum toxin therapy for treatment of urological neurological conditions
|
US7470431B2
(en)
*
|
1997-07-15 |
2008-12-30 |
The Regents Of The University Of Colorado |
Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer
|
US7449192B2
(en)
|
1997-07-15 |
2008-11-11 |
The Regents Of The University Of Colorado |
Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
|
GB9721189D0
(en)
*
|
1997-10-08 |
1997-12-03 |
Speywood Lab The Limited |
Analgesic conjugates
|
US6600626B2
(en)
*
|
1998-07-17 |
2003-07-29 |
Hitachi, Ltd. |
Magnetic disk apparatus
|
US6376460B2
(en)
*
|
1998-08-07 |
2002-04-23 |
Flinders Technologies Pty. Ltd. |
Method of modulating cellular activity
|
GB9818548D0
(en)
|
1998-08-25 |
1998-10-21 |
Microbiological Res Authority |
Treatment of mucas hypersecretion
|
US20080249019A1
(en)
*
|
1998-08-25 |
2008-10-09 |
Syntaxin, Ltd. |
Treatment of mucus hypersecretion
|
US20040071736A1
(en)
*
|
1998-08-25 |
2004-04-15 |
Health Protection Agency |
Methods and compounds for the treatment of mucus hypersecretion
|
US8790897B2
(en)
*
|
1998-08-25 |
2014-07-29 |
Syntaxin Ltd. |
Treatment of mucus hypersecretion
|
GB9824282D0
(en)
*
|
1998-11-05 |
1998-12-30 |
Microbiological Research Agenc |
Delivery of superoxide dismutase to neuronal cells
|
JP2000169389A
(ja)
*
|
1998-12-08 |
2000-06-20 |
Sumitomo Pharmaceut Co Ltd |
触覚異常治療剤
|
US20040120891A1
(en)
*
|
1998-12-21 |
2004-06-24 |
Craig Hill |
Compounds for intracellular delivery of therapeutic moieties to nerve cells
|
US6652864B1
(en)
*
|
1998-12-21 |
2003-11-25 |
Asilomar Pharmaceuticals, Inc. |
Compounds for intracellular delivery of therapeutic moieties to nerve cells
|
GB9907429D0
(en)
*
|
1999-03-31 |
1999-05-26 |
Microbiological Res Authority |
Modulation of C-fibre activity
|
US6776990B2
(en)
|
1999-04-08 |
2004-08-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pancreatitis
|
US20080032931A1
(en)
*
|
1999-08-25 |
2008-02-07 |
Steward Lance E |
Activatable clostridial toxins
|
US20090018081A1
(en)
*
|
1999-08-25 |
2009-01-15 |
Allergan, Inc. |
Activatable clostridial toxins
|
WO2001014570A1
(en)
*
|
1999-08-25 |
2001-03-01 |
Allergan Sales, Inc. |
Activatable recombinant neurotoxins
|
US7740868B2
(en)
|
1999-08-25 |
2010-06-22 |
Allergan, Inc. |
Activatable clostridial toxins
|
US20030180289A1
(en)
*
|
1999-09-23 |
2003-09-25 |
Foster Keith Alan |
Inhibition of secretion from non-neuronal cells
|
GB9922554D0
(en)
*
|
1999-09-23 |
1999-11-24 |
Microbiological Res Authority |
Inhibition of secretion from non-neuronal cells
|
US20080038274A1
(en)
|
1999-09-23 |
2008-02-14 |
Foster Keith A |
Inhibition of secretion from non-neuronal cells
|
US6113915A
(en)
|
1999-10-12 |
2000-09-05 |
Allergan Sales, Inc. |
Methods for treating pain
|
EP1234043B1
(de)
*
|
1999-12-02 |
2004-03-10 |
Health Protection Agency |
Konstrukte zur verabreichung von therapeutischen wirkstoffen an die neuronzellen
|
US7368532B2
(en)
*
|
1999-12-02 |
2008-05-06 |
Syntaxin Limited |
Constructs for delivery of therapeutic agents to neuronal cells
|
US7838008B2
(en)
|
1999-12-07 |
2010-11-23 |
Allergan, Inc. |
Methods for treating diverse cancers
|
US7838007B2
(en)
|
1999-12-07 |
2010-11-23 |
Allergan, Inc. |
Methods for treating mammary gland disorders
|
US6641820B1
(en)
*
|
2000-01-19 |
2003-11-04 |
Allergan, Inc. |
Clostridial toxin derivatives and methods to treat pain
|
US7138127B1
(en)
|
2000-01-19 |
2006-11-21 |
Allergan, Inc. |
Clostridial toxin derivatives and methods for treating pain
|
US6500436B2
(en)
|
2000-01-19 |
2002-12-31 |
Allergan, Inc. |
Clostridial toxin derivatives and methods for treating pain
|
US6821520B2
(en)
|
2000-02-15 |
2004-11-23 |
Allergan, Inc. |
Clostridial toxin therapy for Hashimoto's thyroiditis
|
US6464986B1
(en)
*
|
2000-04-14 |
2002-10-15 |
Allegan Sales, Inc. |
Method for treating pain by peripheral administration of a neurotoxin
|
US6565870B1
(en)
*
|
2000-04-28 |
2003-05-20 |
Allergan, Inc. |
Methods for treating bone tumors
|
US20020077775A1
(en)
*
|
2000-05-25 |
2002-06-20 |
Schork Nicholas J. |
Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
|
US20030195707A1
(en)
*
|
2000-05-25 |
2003-10-16 |
Schork Nicholas J |
Methods of dna marker-based genetic analysis using estimated haplotype frequencies and uses thereof
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
US20050214327A1
(en)
*
|
2000-06-02 |
2005-09-29 |
Allergan, Inc. |
Neurotoxin-containing suppositories and related methods
|
US6306423B1
(en)
|
2000-06-02 |
2001-10-23 |
Allergan Sales, Inc. |
Neurotoxin implant
|
US6306403B1
(en)
|
2000-06-14 |
2001-10-23 |
Allergan Sales, Inc. |
Method for treating parkinson's disease with a botulinum toxin
|
JP2004521067A
(ja)
*
|
2000-06-28 |
2004-07-15 |
サンダース,イラ |
動物(哺乳動物)における有用な用途を目的とする破傷風毒素の使用方法
|
DE10035156A1
(de)
*
|
2000-07-19 |
2002-02-07 |
Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh |
Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
|
US20040219619A1
(en)
*
|
2000-07-21 |
2004-11-04 |
Ester Fernandez-Salas |
Methods of identifying compounds that alter toxin persistence and/or protease activity
|
US7491799B2
(en)
|
2000-07-21 |
2009-02-17 |
Allergan, Inc. |
Modified botulinum neurotoxins
|
US7691983B2
(en)
|
2000-07-21 |
2010-04-06 |
Allergan, Inc. |
Chimera botulinum toxin type E
|
DK2364734T3
(en)
*
|
2000-07-21 |
2017-10-30 |
Revance Therapeutics Inc |
Biological multicomponent transport systems
|
US6903187B1
(en)
*
|
2000-07-21 |
2005-06-07 |
Allergan, Inc. |
Leucine-based motif and clostridial neurotoxins
|
US20030219462A1
(en)
*
|
2000-07-21 |
2003-11-27 |
Allergan Sales, Inc |
Clostridial neurotoxin compositions and modified clostridial neurotoxins
|
US6831059B2
(en)
*
|
2000-10-20 |
2004-12-14 |
Allergan, Inc. |
Compositions and methods for treating gonadotrophin related illnesses
|
US6827931B1
(en)
|
2000-10-20 |
2004-12-07 |
Allergan, Inc. |
Method for treating endocrine disorders
|
US20020127247A1
(en)
|
2000-11-17 |
2002-09-12 |
Allergen Sales, Inc. |
Modified clostridial neurotoxins with altered biological persistence
|
US7223577B2
(en)
*
|
2000-11-17 |
2007-05-29 |
Allergan, Inc. |
Post-translational modifications and Clostridial neurotoxins
|
US7273722B2
(en)
*
|
2000-11-29 |
2007-09-25 |
Allergan, Inc. |
Neurotoxins with enhanced target specificity
|
US6787517B1
(en)
*
|
2000-12-29 |
2004-09-07 |
Allergan, Inc. |
Agent and methods for treating pain
|
US20070048335A1
(en)
*
|
2000-12-29 |
2007-03-01 |
Allergan, Inc. |
Methods for treating pain and hyperhidrosis
|
CA2367636C
(en)
*
|
2001-04-12 |
2010-05-04 |
Lisa Mckerracher |
Fusion proteins
|
JP2005511012A
(ja)
*
|
2001-08-10 |
2005-04-28 |
セローノ ジェネティクス インスティテュート ソシエテ アノニム |
ヒトcDNAおよびタンパク質およびその使用
|
US7332567B2
(en)
*
|
2001-08-28 |
2008-02-19 |
Allergan, Inc. |
Fret protease assays for clostridial toxins
|
US8022172B2
(en)
*
|
2001-08-28 |
2011-09-20 |
Allergan, Inc. |
Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity
|
US7208285B2
(en)
*
|
2001-08-28 |
2007-04-24 |
Allergan, Inc. |
Fret protease assays for botulinum serotype A/E toxins
|
US7374896B2
(en)
*
|
2001-08-28 |
2008-05-20 |
Allergan, Inc. |
GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
|
US6623742B2
(en)
|
2001-09-17 |
2003-09-23 |
Allergan, Inc. |
Methods for treating fibromyalgia
|
US7255866B2
(en)
|
2001-09-17 |
2007-08-14 |
Allergan, Inc. |
Botulinum toxin therapy for fibromyalgia
|
CA2369810C
(en)
|
2002-01-30 |
2007-08-07 |
1474791 Ontario Limited |
Method of treating pain
|
US20050106183A1
(en)
*
|
2002-01-31 |
2005-05-19 |
Lamb Gregory B. |
Method of treating pain
|
US7022329B2
(en)
*
|
2002-02-25 |
2006-04-04 |
Allergan, Inc. |
Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
|
US6688311B2
(en)
*
|
2002-03-14 |
2004-02-10 |
Allergan, Inc. |
Method for determining effect of a clostridial toxin upon a muscle
|
US7140371B2
(en)
*
|
2002-03-14 |
2006-11-28 |
Allergan, Inc. |
Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
|
US6921538B2
(en)
*
|
2002-05-10 |
2005-07-26 |
Allergan, Inc. |
Therapeutic treatments for neuropsychiatric disorders
|
US7691394B2
(en)
*
|
2002-05-28 |
2010-04-06 |
Botulinum Toxin Research Associates, Inc. |
High-potency botulinum toxin formulations
|
US20040009180A1
(en)
*
|
2002-07-11 |
2004-01-15 |
Allergan, Inc. |
Transdermal botulinum toxin compositions
|
US7183066B2
(en)
*
|
2002-09-27 |
2007-02-27 |
Allergan, Inc. |
Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
|
MXPA05003936A
(es)
*
|
2002-10-15 |
2005-06-17 |
Allergan Inc |
Terapias y procedimientos odontologicos con toxina botulinica.
|
US7238357B2
(en)
*
|
2002-11-05 |
2007-07-03 |
Allergan, Inc. |
Methods for treating ulcers and gastroesophageal reflux disease
|
US20040086532A1
(en)
*
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
US20040115727A1
(en)
*
|
2002-12-11 |
2004-06-17 |
Allergan, Inc., A Corporation |
Evolved clostridial toxins with altered protease specificity
|
EP1594523B1
(de)
*
|
2002-12-20 |
2009-03-25 |
Botulinum Toxin Research Associates, Inc. |
Pharmazeutische zusammensetzungen enthaltend botulinumtoxin und humanes serum-albumin
|
US20060153876A1
(en)
*
|
2003-02-24 |
2006-07-13 |
Ira Sanders |
Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
|
US8071550B2
(en)
|
2003-03-03 |
2011-12-06 |
Allergan, Inc. |
Methods for treating uterine disorders
|
ES2381091T3
(es)
*
|
2003-03-06 |
2012-05-23 |
Botulinum Toxin Research Associates, Inc. |
Tratamiento del dolor facial crónico y cefalea relacionados con la sinusitis con toxina botulínica
|
US7422753B2
(en)
*
|
2003-04-25 |
2008-09-09 |
Allergan, Inc. |
Methods for treating trichotillomania
|
US7390496B2
(en)
*
|
2003-04-25 |
2008-06-24 |
Allergan, Inc. |
Therapeutic treatments for repetitive hand washing
|
US7393537B2
(en)
*
|
2003-04-25 |
2008-07-01 |
Allergan, Inc. |
Botulinum toxin for treatment of obsessive compulsive finger biting disorder
|
US7393538B2
(en)
*
|
2003-04-25 |
2008-07-01 |
Ackerman Alan H |
Clostridial toxin treatment for dermatillomania
|
US7396535B2
(en)
*
|
2003-04-25 |
2008-07-08 |
Ackerman Alan H |
Therapy for obsessive compulsive head banging
|
US6838434B2
(en)
*
|
2003-05-02 |
2005-01-04 |
Allergan, Inc. |
Methods for treating sinus headache
|
US20040226556A1
(en)
|
2003-05-13 |
2004-11-18 |
Deem Mark E. |
Apparatus for treating asthma using neurotoxin
|
US7220422B2
(en)
*
|
2003-05-20 |
2007-05-22 |
Allergan, Inc. |
Methods and compositions for treating eye disorders
|
US20040253274A1
(en)
*
|
2003-06-11 |
2004-12-16 |
Allergan, Inc. |
Use of a clostridial toxin to reduce appetite
|
GB0321344D0
(en)
*
|
2003-09-11 |
2003-10-15 |
Health Prot Agency |
Re-targeted toxin conjugates
|
US8734810B2
(en)
|
2003-10-29 |
2014-05-27 |
Allergan, Inc. |
Botulinum toxin treatments of neurological and neuropsychiatric disorders
|
US8048423B2
(en)
*
|
2003-12-09 |
2011-11-01 |
Allergan, Inc. |
Botulinum toxin therapy for skin disorders
|
US8871224B2
(en)
|
2003-12-09 |
2014-10-28 |
Allergan, Inc. |
Botulinum toxin therapy for skin disorders
|
US7270287B2
(en)
*
|
2004-01-06 |
2007-09-18 |
Allergan, Inc. |
Botulinum toxin treatment for kinesia
|
US6974579B2
(en)
*
|
2004-01-08 |
2005-12-13 |
Allergan, Inc. |
Methods for treating vascular disorders
|
US20050191321A1
(en)
|
2004-02-26 |
2005-09-01 |
Allergan, Inc. |
Methods for treating headache
|
US9078892B2
(en)
*
|
2004-02-26 |
2015-07-14 |
Allergan, Inc. |
Methods for treating pain and for treating a medication overuse disorder
|
US20100266638A1
(en)
*
|
2004-02-26 |
2010-10-21 |
Allergan, Inc. |
Headache treatment method
|
US9211248B2
(en)
|
2004-03-03 |
2015-12-15 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
US8974774B2
(en)
*
|
2004-03-03 |
2015-03-10 |
Revance Therapeutics, Inc. |
Compositions and methods for topical diagnostic and therapeutic transport
|
US20050220821A1
(en)
*
|
2004-03-31 |
2005-10-06 |
Allergan, Inc. |
Pressure sore treatment
|
US20050220734A1
(en)
*
|
2004-04-02 |
2005-10-06 |
Allergan, Inc. |
Therapy for melanin related afflictions
|
US7691381B2
(en)
|
2004-04-15 |
2010-04-06 |
Allergan, Inc. |
Stabilized biodegradable neurotoxin implants
|
US6991789B2
(en)
*
|
2004-06-29 |
2006-01-31 |
Allergas, Inc. |
Methods of modulating intracellular degradation rates of toxins
|
US7514088B2
(en)
*
|
2005-03-15 |
2009-04-07 |
Allergan, Inc. |
Multivalent Clostridial toxin derivatives and methods of their use
|
US7811584B2
(en)
*
|
2004-06-30 |
2010-10-12 |
Allergan, Inc. |
Multivalent clostridial toxins
|
US20060024331A1
(en)
*
|
2004-08-02 |
2006-02-02 |
Ester Fernandez-Salas |
Toxin compounds with enhanced membrane translocation characteristics
|
EP1784420B1
(de)
*
|
2004-09-01 |
2008-12-03 |
Allergan, Inc. |
Abbaubare clostridientoxine
|
US7429386B2
(en)
*
|
2004-09-03 |
2008-09-30 |
Allergan, Inc. |
Stretch mark treatment
|
US7179474B2
(en)
*
|
2004-09-03 |
2007-02-20 |
Allergan, Inc. |
Methods for treating a buttock deformity
|
DE102004043009A1
(de)
|
2004-09-06 |
2006-03-23 |
Toxogen Gmbh |
Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
|
US7399607B2
(en)
*
|
2004-09-22 |
2008-07-15 |
Allergan, Inc. |
Fluorescence polarization assays for determining clostridial toxin activity
|
US20060073208A1
(en)
*
|
2004-10-01 |
2006-04-06 |
Allergan, Inc. |
Cosmetic neurotoxin compositions and methods
|
US7897147B2
(en)
*
|
2004-10-20 |
2011-03-01 |
Allergan, Inc. |
Treatment of premenstrual disorders
|
US7785606B2
(en)
*
|
2004-11-22 |
2010-08-31 |
New York University |
Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
|
US8399400B2
(en)
|
2004-12-01 |
2013-03-19 |
Syntaxin, Ltd. |
Fusion proteins
|
US7659092B2
(en)
|
2004-12-01 |
2010-02-09 |
Syntaxin, Ltd. |
Fusion proteins
|
GB0426397D0
(en)
*
|
2004-12-01 |
2005-01-05 |
Health Prot Agency |
Fusion proteins
|
CA2595115C
(en)
*
|
2004-12-01 |
2014-01-21 |
Health Protection Agency |
Fusion proteins for treating, preventing or ameliorating pain
|
GB0426394D0
(en)
*
|
2004-12-01 |
2005-01-05 |
Health Prot Agency |
Fusion proteins
|
US8512984B2
(en)
|
2004-12-01 |
2013-08-20 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
US8603779B2
(en)
|
2004-12-01 |
2013-12-10 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
US8778634B2
(en)
|
2004-12-01 |
2014-07-15 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
WO2006059105A2
(en)
*
|
2004-12-01 |
2006-06-08 |
Health Protection Agency |
Non-cytotoxic Protein Conjugates
|
FR2879462B1
(fr)
*
|
2004-12-21 |
2008-12-26 |
Sod Conseils Rech Applic |
Utilisation de toxine botulique pour une insensibilisation locale prolongee
|
US7655244B2
(en)
|
2005-02-01 |
2010-02-02 |
Allergan, Inc. |
Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
|
US7749515B2
(en)
*
|
2005-02-01 |
2010-07-06 |
Allergan, Inc. |
Targeted delivery of botulinum toxin to the sphenopalatine ganglion
|
ZA200707352B
(en)
|
2005-03-03 |
2009-04-29 |
Revance Therapeutics Inc |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
AU2006227816B2
(en)
*
|
2005-03-15 |
2012-04-05 |
Allergan, Inc. |
Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
|
US8021859B2
(en)
*
|
2005-03-15 |
2011-09-20 |
Allergan, Inc. |
Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
|
US7731411B2
(en)
*
|
2005-04-04 |
2010-06-08 |
Schlumberger Technology Corporation |
Circulating fluid system for powder fluidization and method of performing same
|
ES2259928B1
(es)
*
|
2005-04-08 |
2007-11-01 |
Lipotec, S.A. |
Composicion cosmetica o dermofarmaceutica que comprende peptidos derivados de encefalinas para reducir y/o eliminar arrugas faciales.
|
DE102005019302A1
(de)
|
2005-04-26 |
2006-11-16 |
Toxogen Gmbh |
Carrier zum Targeting von Nervenzellen
|
US7419675B2
(en)
*
|
2005-05-26 |
2008-09-02 |
Allergan, Inc. |
Method for treating peritoneal adhesions
|
US8105611B2
(en)
*
|
2005-06-17 |
2012-01-31 |
Allergan, Inc. |
Treatment of autoimmune disorder with a neurotoxin
|
US7910116B2
(en)
*
|
2005-08-24 |
2011-03-22 |
Allergan, Inc. |
Use of a botulinum toxin to improve gastric emptying and/or to treat GERD
|
DK1926744T4
(en)
|
2005-09-19 |
2019-01-28 |
Allergan Inc |
CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
|
US8168206B1
(en)
|
2005-10-06 |
2012-05-01 |
Allergan, Inc. |
Animal protein-free pharmaceutical compositions
|
US7824694B2
(en)
*
|
2006-01-12 |
2010-11-02 |
Allergan, Inc. |
Methods for enhancing therapeutic effects of a neurotoxin
|
US20070178121A1
(en)
*
|
2006-01-27 |
2007-08-02 |
Allergan, Inc. |
Methods for enhancing skin treatments
|
WO2007106115A1
(en)
|
2006-03-14 |
2007-09-20 |
Allergan, Inc. |
Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
|
US7794386B2
(en)
|
2006-03-15 |
2010-09-14 |
Allergan, Inc. |
Methods for facilitating weight loss
|
US7811586B2
(en)
*
|
2006-05-02 |
2010-10-12 |
Allergan, Inc. |
Methods for alleviating testicular pain
|
CN101074935B
(zh)
*
|
2006-05-19 |
2011-03-23 |
清华大学 |
探测器阵列及设备
|
GB0610867D0
(en)
|
2006-06-01 |
2006-07-12 |
Syntaxin Ltd |
Treatment of pain
|
WO2008008803A2
(en)
*
|
2006-07-11 |
2008-01-17 |
Allergan, Inc. |
Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
|
AU2007347781B2
(en)
|
2006-07-11 |
2013-10-03 |
Allergan, Inc. |
Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
|
WO2008011157A2
(en)
*
|
2006-07-20 |
2008-01-24 |
The General Hospital Corporation |
Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
|
US9061025B2
(en)
*
|
2006-08-31 |
2015-06-23 |
Allergan, Inc. |
Methods for selecting headache patients responsive to botulinum toxin therapy
|
US20080092910A1
(en)
*
|
2006-10-18 |
2008-04-24 |
Allergan, Inc. |
Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures
|
US20080113051A1
(en)
*
|
2006-11-13 |
2008-05-15 |
Allergan, Inc. |
Methods for alleviating tattoo pain
|
BRPI0720729A2
(pt)
*
|
2006-12-29 |
2014-04-08 |
Revance Therapeutics Inc |
Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa.
|
KR101722038B1
(ko)
*
|
2007-07-26 |
2017-04-03 |
레반스 테라퓨틱스, 아이엔씨. |
항미생물 펩티드, 조성물, 및 이용 방법
|
MX2010004488A
(es)
*
|
2007-10-23 |
2010-06-17 |
Allergan Inc |
Metodos para tratar inflamacion neurogenica cronica usando toxinas clostridiales modificadas.
|
CN101918021A
(zh)
*
|
2007-10-23 |
2010-12-15 |
阿勒根公司 |
使用经修饰的梭菌毒素治疗泌尿生殖系统神经疾病的方法
|
US8483831B1
(en)
|
2008-02-15 |
2013-07-09 |
Holaira, Inc. |
System and method for bronchial dilation
|
US8470337B2
(en)
*
|
2008-03-13 |
2013-06-25 |
Allergan, Inc. |
Therapeutic treatments using botulinum neurotoxin
|
US8617571B2
(en)
|
2008-04-03 |
2013-12-31 |
Allergan, Inc. |
Suture line administration technique using botulinum toxin
|
KR101719824B1
(ko)
|
2008-05-09 |
2017-04-04 |
호라이라 인코포레이티드 |
기관지나무 치료용 시스템, 어셈블리 및 방법
|
US8796216B2
(en)
|
2008-06-12 |
2014-08-05 |
Syntaxin Limited |
Suppression of neuroendocrine diseases
|
JP5799397B2
(ja)
|
2008-06-12 |
2015-10-28 |
イプセン・バイオイノベーション・リミテッドIpsen Bioinnovation Limited |
癌の抑制
|
EP3590956A1
(de)
*
|
2008-06-12 |
2020-01-08 |
Ipsen Bioinnovation Limited |
Unterdrückung von neuroendokrinen erkrankungen
|
CA2733283A1
(en)
*
|
2008-08-29 |
2010-03-04 |
Merz Pharma Gmbh & Co. Kgaa |
Clostridial neurotoxins with altered persistency
|
GB0820970D0
(en)
|
2008-11-17 |
2008-12-24 |
Syntaxin Ltd |
Suppression of cancer
|
US20100124559A1
(en)
*
|
2008-11-20 |
2010-05-20 |
Allergan, Inc. |
Early Treatment and Prevention of Increased Muscle Tonicity
|
US8259461B2
(en)
*
|
2008-11-25 |
2012-09-04 |
Micron Technology, Inc. |
Apparatus for bypassing faulty connections
|
US9066851B2
(en)
|
2008-12-04 |
2015-06-30 |
Botulinum Toxin Research Associates, Inc. |
Extended length botulinum toxin formulation for human or mammalian use
|
CN105833254A
(zh)
|
2008-12-10 |
2016-08-10 |
阿勒根公司 |
梭菌毒素药物组合物
|
KR102005930B1
(ko)
|
2008-12-31 |
2019-07-31 |
레반스 테라퓨틱스, 아이엔씨. |
주사용 보툴리눔 독소 제제
|
RU2543650C2
(ru)
*
|
2009-03-13 |
2015-03-10 |
Аллерган, Инк. |
Иммунологические тесты на активность эндопептидаз с измененной нацеленностью
|
BRPI1015938A2
(pt)
|
2009-06-25 |
2016-09-27 |
Revance Therapeutics Inc |
formulações da toxina botulínica livre de albumina
|
CA2770185C
(en)
|
2009-08-17 |
2019-04-09 |
East Carolina University |
Fast acting snare-cleaving enzymes
|
WO2011023213A1
(en)
*
|
2009-08-28 |
2011-03-03 |
Merz Pharma Gmbh & Co. Kgaa |
Modified chemodenervating agents
|
WO2011041483A2
(en)
|
2009-09-30 |
2011-04-07 |
Toxcure, Inc. |
Use of botulinum neurotoxin to treat substance addictions
|
EP2926757B1
(de)
|
2009-10-27 |
2023-01-25 |
Nuvaira, Inc. |
Freisetzungsvorrichtungen mit kühlbaren energieemissionsanordnungen
|
AU2010319477A1
(en)
|
2009-11-11 |
2012-05-24 |
Holaira, Inc. |
Systems, apparatuses, and methods for treating tissue and controlling stenosis
|
US8911439B2
(en)
|
2009-11-11 |
2014-12-16 |
Holaira, Inc. |
Non-invasive and minimally invasive denervation methods and systems for performing the same
|
AU2010353292A1
(en)
|
2009-12-16 |
2012-07-12 |
Allergan, Inc. |
Modified Clostridial toxins comprising an integrated protease cleavage site-binding domain
|
EP3034511A1
(de)
|
2010-01-25 |
2016-06-22 |
Allergan, Inc. |
Verfahren zur intrazellulären umwandlung von einkettigen proteinen in ihre zweikettige form
|
MX2012013381A
(es)
|
2010-05-20 |
2013-02-21 |
Allergan Inc |
Toxinas de clostridium degradables.
|
JP5779848B2
(ja)
*
|
2010-07-30 |
2015-09-16 |
セイコーエプソン株式会社 |
液体吐出装置、液体吐出装置の駆動方法以上
|
WO2012048246A1
(en)
|
2010-10-08 |
2012-04-12 |
Allergan, Inc. |
Reduction of antibody response against botulinum neurotoxin and variants thereof
|
CA2819635A1
(en)
*
|
2010-12-01 |
2012-06-07 |
Spinal Modulation, Inc. |
Directed delivery of agents to neural anatomy
|
DK2661297T3
(en)
*
|
2011-01-04 |
2018-09-03 |
Sanofi Aventis Deutschland |
INJECTION DEVICE, INCLUDING A FILLED SPRAY AND A SAFETY DEVICE
|
US20120195878A1
(en)
|
2011-01-28 |
2012-08-02 |
Allergan, Inc. |
Protocol for the administration of botulinum toxins
|
JP2014510045A
(ja)
|
2011-02-08 |
2014-04-24 |
ハロザイム インコーポレイテッド |
ヒアルロナン分解酵素の組成物および脂質製剤ならびに良性前立腺肥大症の治療のためのその使用
|
GB201108108D0
(en)
*
|
2011-05-16 |
2011-06-29 |
Syntaxin Ltd |
Therapeutic fusion proteins
|
US8992941B2
(en)
|
2011-07-08 |
2015-03-31 |
Allergan, Inc. |
Method for treatment of esophageal spasm
|
US20140140983A1
(en)
|
2011-07-08 |
2014-05-22 |
Allergan, Inc. |
Method for treatment of autonomic nervous system disorders
|
KR20140082956A
(ko)
|
2011-07-20 |
2014-07-03 |
알러간, 인코포레이티드 |
지방 침착물의 치료방법에 이용하기 위한 보툴리눔 독소
|
US9393291B2
(en)
|
2012-04-12 |
2016-07-19 |
Botulinum Toxin Research Associates, Inc. |
Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
|
BR112014029585A2
(pt)
|
2012-05-30 |
2017-07-25 |
Harvard College |
neurotoxina botulínica engendrada
|
US20140056870A1
(en)
*
|
2012-08-27 |
2014-02-27 |
Allergan, Inc. |
Fusion proteins
|
US9005628B2
(en)
|
2012-10-04 |
2015-04-14 |
Dublin City University |
Biotherapy for pain
|
GB201219024D0
(en)
|
2012-10-23 |
2012-12-05 |
Syntaxin Ltd |
Assay
|
US9398933B2
(en)
|
2012-12-27 |
2016-07-26 |
Holaira, Inc. |
Methods for improving drug efficacy including a combination of drug administration and nerve modulation
|
US9315549B2
(en)
|
2013-01-28 |
2016-04-19 |
New York University |
Treatment methods using atoxic neurotoxin derivatives
|
GB201312317D0
(en)
|
2013-07-09 |
2013-08-21 |
Syntaxin Ltd |
Cationic neurotoxins
|
US10149893B2
(en)
|
2013-09-24 |
2018-12-11 |
Allergan, Inc. |
Methods for modifying progression of osteoarthritis
|
US9216210B2
(en)
|
2013-12-23 |
2015-12-22 |
Dublin City University |
Multiprotease therapeutics for chronic pain
|
CN106133522B
(zh)
*
|
2014-02-19 |
2018-10-12 |
莫茨药物股份两合公司 |
在体外试验系统中用于使细胞对肉毒神经毒素的敏感性标准化和增加的神经节苷脂
|
US10527620B2
(en)
|
2014-07-07 |
2020-01-07 |
Allergan, Inc. |
Method of detecting cleaved SNAP25 in tissue samples
|
US9901627B2
(en)
|
2014-07-18 |
2018-02-27 |
Revance Therapeutics, Inc. |
Topical ocular preparation of botulinum toxin for use in ocular surface disease
|
US11484580B2
(en)
|
2014-07-18 |
2022-11-01 |
Revance Therapeutics, Inc. |
Topical ocular preparation of botulinum toxin for use in ocular surface disease
|
CA2969463A1
(en)
|
2014-12-09 |
2016-06-16 |
New York University |
Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
|
EP3822286A1
(de)
|
2015-01-09 |
2021-05-19 |
Ipsen Bioinnovation Limited |
Kationische neurotoxine
|
CN115925835A
(zh)
|
2015-03-26 |
2023-04-07 |
哈佛大学校长及研究员协会 |
工程改造的肉毒杆菌神经毒素
|
WO2017035508A1
(en)
|
2015-08-27 |
2017-03-02 |
Collier R John |
Compositions and methods for treatment of pain
|
GB201517450D0
(en)
|
2015-10-02 |
2015-11-18 |
Ipsen Biopharm Ltd |
Method
|
AU2017277905B2
(en)
|
2016-06-08 |
2022-04-14 |
Children's Medical Center Corporation |
Engineered Botulinum neurotoxins
|
EP3263710A1
(de)
|
2016-07-01 |
2018-01-03 |
Ipsen Biopharm Limited |
Herstellung von aktivierten clostridien-neurotoxinen
|
ES2939001T3
(es)
|
2016-07-08 |
2023-04-18 |
Childrens Medical Center |
Una neurotoxina botulínica novedosa y sus derivados
|
WO2018039506A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Engineered botulinum neurotoxin
|
WO2018038301A1
(en)
|
2016-08-26 |
2018-03-01 |
Hugel Inc. |
Stabilized liquid formulation of botulinum toxin and preparation method thereof
|
CN109803672A
(zh)
|
2016-09-13 |
2019-05-24 |
阿勒根公司 |
稳定的非蛋白质梭菌毒素组合物
|
TW201814045A
(zh)
|
2016-09-16 |
2018-04-16 |
英商艾普森生物製藥有限公司 |
製造雙鏈梭狀芽孢桿菌神經毒素之方法
|
CN109790204A
(zh)
|
2016-09-29 |
2019-05-21 |
益普生生物制药有限公司 |
杂合神经毒素
|
EP3312290A1
(de)
|
2016-10-18 |
2018-04-25 |
Ipsen Biopharm Limited |
Zellulärer vamp-spaltungstest
|
PL3529616T3
(pl)
|
2016-10-20 |
2024-03-18 |
President And Fellows Of Harvard College |
Testy in vitro i komórkowe do pomiaru aktywności neurotoksyn botulinowych
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
EP3687566A2
(de)
|
2017-09-29 |
2020-08-05 |
Children's Medical Center Corporation |
Neurotoxinähnliches toxin und dessen verwendungen
|
EP3470054B1
(de)
|
2017-10-11 |
2023-09-20 |
Hugel Inc. |
Mikrostrukturformulierungstechniken für botulinumtoxin
|
US10792400B2
(en)
|
2017-10-12 |
2020-10-06 |
Hugel Inc. |
Microstructure formulation techniques for botulinum toxin
|
US10525111B2
(en)
|
2017-10-12 |
2020-01-07 |
Hugel, Inc. |
Microstructure formulation techniques for botulinum toxin
|
MX2020007596A
(es)
|
2018-01-29 |
2020-09-03 |
Ipsen Biopharm Ltd |
Neurotoxinas botulinicas para escindir una proteina de receptor de union a factor sensible a n-etilmaleimida soluble (snare) no neuronal.
|
JP7186228B2
(ja)
|
2018-02-26 |
2022-12-08 |
イプセン バイオファーム リミテッド |
非細胞毒性プロテアーゼの注入を案内するための超音波の使用
|
JP2021525251A
(ja)
|
2018-05-21 |
2021-09-24 |
イプセン バイオファーム リミテッドIpsen Biopharm Limited |
骨癌誘発性アロディニアの抑制
|
GB201815817D0
(en)
|
2018-09-28 |
2018-11-14 |
Ispen Biopharm Ltd |
Clostridial neurotoxins comprising and exogenous activation loop
|
EP3660509B1
(de)
|
2018-11-29 |
2022-03-09 |
Hugel Inc. |
Zellbasiertes verfahren zur bestimmung der aktivität von botulinumtoxin
|
US20220016221A1
(en)
|
2018-12-05 |
2022-01-20 |
Ipsen Biopharm Limited |
Treatment of symptoms of traumatic brain injury
|
GB201900621D0
(en)
|
2019-01-16 |
2019-03-06 |
Ipsen Biopharm Ltd |
Labelled polypeptides
|
GB201914034D0
(en)
|
2019-09-30 |
2019-11-13 |
Ipsen Biopharm Ltd |
Treatment of neurological disorders
|
GB202100566D0
(en)
|
2021-01-15 |
2021-03-03 |
Ipsen Biopharm Ltd |
Treatment of brain damage
|
GB202104294D0
(en)
|
2021-03-26 |
2021-05-12 |
Ipsen Biopharm Ltd |
Clostridial neurotoxins comprising an exogenous activation loop
|
JP2024513191A
(ja)
|
2021-03-30 |
2024-03-22 |
イプセン バイオファーム リミテッド |
疼痛及び炎症性障害の処置
|
CA3211472A1
(en)
|
2021-03-30 |
2022-10-06 |
Mikhail KALINICHEV |
Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
|
GB202116795D0
(en)
|
2021-11-22 |
2022-01-05 |
Ipsen Biopharm Ltd |
Treatment of visceral pain
|
WO2023105289A1
(en)
|
2021-12-06 |
2023-06-15 |
Dublin City University |
Methods and compositions for the treatment of pain
|
GB202214232D0
(en)
|
2022-09-28 |
2022-11-09 |
Ispen Biopharm Ltd |
Clostridial neurotoxins comprising an activating exogenous protease cleavage site
|
GB202214229D0
(en)
|
2022-09-28 |
2022-11-09 |
Ipsen Biopharm Ltd |
Clostridial neurotoxins comprising an activating endosomal protease cleavage site
|